Haleon is a global consumer health company formed in July 2022 through the spin-off of GSK’s consumer healthcare business. Headquartered in London, the company brings together a portfolio of trusted brands in over-the-counter health products, delivering solutions that support everyday wellness. With a heritage rooted in decades of research, Haleon leverages scientific expertise to address the evolving needs of consumers worldwide.
The company’s primary business activities encompass the development, manufacturing and marketing of a wide range of consumer health products. Its product categories include oral health, pain relief, respiratory care, vitamins and mineral supplements, digestive health and wellness. Signature brands under the Haleon umbrella include Sensodyne, Centrum, Voltaren, Advil, Panadol and Tums, each positioned to meet specific health and wellness demands across diverse demographic segments.
Haleon operates in more than 120 markets, with manufacturing facilities and research centers strategically located across North America, Europe, Asia Pacific, Latin America and Africa. The company’s distribution network spans pharmacies, supermarkets, mass merchandisers and e-commerce platforms, enabling broad consumer access. Collaborations with healthcare professionals, academic institutions and strategic partners support ongoing product innovation, consumer education and quality assurance.
Under the leadership of Chief Executive Officer Brian McNamara, Haleon is focused on driving sustainable growth through targeted investments in research and development, digital marketing and supply chain optimization. The company has also committed to ambitious environmental and social targets, including carbon reduction, responsible sourcing and community engagement initiatives, reinforcing its mission to empower healthier lives and foster long-term value for stakeholders.
AI Generated. May Contain Errors.
Free HLN Stock Alerts